Genzyme Wins Restrictions On Generic Arthritis Drug Price

Law360, New York (January 5, 2012, 8:43 PM EST) -- Genzyme Corp. has won a preliminary injunction in its infringement suit against Seikagaku Corp. over osteoarthritis knee pain treatment Synvisc-One, setting a minimum price at which the Japanese pharmaceutical maker can sell its lower-cost generic, Genzyme announced Thursday.

Pending trial, Seikagaku will be allowed to sell the recently approved Gel-One generic product, but not for less than $547.60 per unit, the average market price for Genzyme's drug, according to the order.

“In the absence of injunctive relief directed at the defendants’ pricing of the Gel-One product,...
To view the full article, register now.